Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease

References

• TakeuchiKYahiKKatoSRoles of prostaglandin E-receptor subtypes in gastric and duodenal bicarbonate secretion in ratsGastroenterology19971135155315599352857
   PubMed Web of Science ®Google Scholar
• TakeuchiKAiharaEHayashiMRole of prostaglandin E receptor subtypes in gastroduodenal HCO3 secretionMed Chem20051439540316789896
   PubMed Web of Science ®Google Scholar
• RostomADubeCWellsGAPrevention of NSAID-induced gastroduodenal ulcersCochrane Database Syst Rev20024CD00229612519573
   PubMedGoogle Scholar
• Rodriguez-StanleySRedingerNMinerPBEffect of naproxen on gastric acid secretion and gastric pHAliment Pharmacol Ther200623121719172416817915
   PubMed Web of Science ®Google Scholar
• BeckerJCGrosserNWaltkeCBeyond gastric acid reduction: Proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cellsBiochem Biophys Res Commun200634531014102116712795
   PubMed Web of Science ®Google Scholar
• BlandizziCGherardiGNataleGProtective action of omeprazole against gastric mucosal injury induced by hemorrhagic shock in ratsDig Dis Sci19943910210920177924729
   PubMed Web of Science ®Google Scholar
• BlandizziCGherardiGMarveggioCMechanisms of protection by omeprazole against experimental gastric mucosal damage in ratsDigestion19955632202297657048
   PubMed Web of Science ®Google Scholar
• WandallJHEffects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245Gut19923356176211319381
   PubMed Web of Science ®Google Scholar
• SuzukiMNakamuraMMoriMLansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pyloriJ Clin Gastroenterol199520Suppl 2S93S967594353
   PubMed Web of Science ®Google Scholar
• GoldsteinJLJohansonJFHawkeyCJClinical trial: Healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazoleAliment Pharmacol Ther20072681101111117894652
   PubMed Web of Science ®Google Scholar
• AgrawalNMCampbellDRSafdiMASuperiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study GroupArch Intern Med2000160101455146110826458
   PubMedGoogle Scholar
• ScheimanJMYeomansNDTalleyNJPrevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitorsAm J Gastroenterol2006101470171016494585
   PubMed Web of Science ®Google Scholar
• MusumbaCPrichardDMPirmohamedMReview article: Cellular and molecular mechanisms of NSAID-induced peptic ulcersAliment Pharmacol Ther200930651753119575764
   PubMed Web of Science ®Google Scholar
• GeisGSSteadHWallemarkCBPrevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesionsJ Rheumatol199118Suppl 281114
   Google Scholar
• KaufmanDKellyJPRosenbergLRecent patterns of medication use in the ambulatory adult population of the United States: The Slone surveyJAMA2002287333734411790213
   PubMed Web of Science ®Google Scholar
• Garcia RodriguezLAHernandez-DiazSRelative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugsEpidemiology200112557057611505178
   PubMed Web of Science ®Google Scholar
• WilcoxCAllisonJBenzulyKConsensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirinClin Gastroenterol Hepatol2006491082108916877048
   PubMed Web of Science ®Google Scholar
• ArmstrongCPBlowerALNon-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcerationGut19872855275323596334
   PubMed Web of Science ®Google Scholar
• LanasAGarcia-RodriguezLAArroyoMTRisk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin, and combinationsGut200655121731173816687434
   PubMed Web of Science ®Google Scholar
• RostomAMuirKDubeCGastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic reviewClin Gastroenterol Hepatol20075781882817556027
   PubMed Web of Science ®Google Scholar
• SilversteinFEFaichGGoldsteinJLGastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety studyJAMA2000284101247125510979111
   PubMed Web of Science ®Google Scholar
• SchnitzerTJBurmesterGRMyslerEComparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomized controlled trialLancet2004364943566567415325831
   PubMed Web of Science ®Google Scholar
• BombardierCLaineLReicinAComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with patients with rheumatoid arthritis. VIGOR Study GroupN Engl J Med2000343201520152811087881
   PubMed Web of Science ®Google Scholar
• BresalierRSSandlerRSQuanHCardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialN Engl J Med2005352111092110215713943
   PubMed Web of Science ®Google Scholar
• SolomonSDMcMurrayJJPfefferMACardiovascular events associated with celecoxib in a clinical trial for colorectal adenoma preventionN Engl J Med2005352111071108015713944
   PubMed Web of Science ®Google Scholar
• KearneyPMBaigentCGodwinJDo selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trialsBMJ200633275531302130816740558
   PubMed Web of Science ®Google Scholar
• GoldsteinJLHochbergMCFortJGClinical trial: The incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) versus enteric-coated naproxen aloneAliment Pharmacol Ther201032340141320497139
   PubMed Web of Science ®Google Scholar
• MinerPBPlachetkaJROrlemansEFortJGSostekMBClinical trial: Evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric coated esomeprazole 20 mg: A randomized, open-label, Phase I study in healthy volunteersAliment Pharmacol Ther201032241442420491746
   PubMed Web of Science ®Google Scholar
• RabeneckLMeasuring dyspepsia-related health in randomized trials: The Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2 specific inhibitorsRheumatology200342Suppl 33239
   Google Scholar
• JaeschkeRSingerJGuyattGHMeasurement of health status. Ascertaining the minimal clinically important differenceControl Clin Trials19891044074152691207
   PubMedGoogle Scholar
• GoldsteinJLHowardKBWaltonSMImpact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complicationsClin Gastroenterol Hepatol20064111337134517088110
   PubMed Web of Science ®Google Scholar
• SturkenboomMCBurkeTATangelderMJAdherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugsAliment Pharmacol Ther20031811–121137114714653834
   PubMed Web of Science ®Google Scholar
• LanasAA review of the gastrointestinal safety data – a gastroenterologist’s perspectiveRheumatology201049Suppl 231019755506
   PubMed Web of Science ®Google Scholar
• ChanFKCryerBGoldsteinJLA novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tractJ Rheumatol200937116717419884267
   PubMed Web of Science ®Google Scholar
• ScheimanJMHindleyCEStrategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse eventsClin Ther201032466767720435236
   PubMed Web of Science ®Google Scholar